Crescent Biopharma Strengthens Leadership Team with Appointment of Three Key Executives

New appointees reinforce the Company's momentum in building a leading oncology therapeutics company Lead asset CR-001, a tetravalent PD-1 x VEGF bispecific antibody, on track for IND filing in the fourth quarter of 2025 Novel ADCs CR-002 and CR-003 on track for development as single...